Lianluo Smart Stock Forecast, Price & News

Wall Street analysts have given Lianluo Smart a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lianluo Smart wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Lianluo Smart saw a drop in short interest in February. As of February 26th, there was short interest totaling 155,800 shares, a drop of 27.4% from the February 11th total of 214,700 shares. Based on an average daily trading volume, of 1,050,000 shares, the short-interest ratio is currently 0.1 days. Currently, 8.0% of the shares of the company are short sold.
View Lianluo Smart's Short Interest.

Lianluo Smart is scheduled to release its next quarterly earnings announcement on Wednesday, June 30th 2021.
View our earnings forecast for Lianluo Smart.

Lianluo Smart's stock was trading at $4.1312 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LLIT shares have increased by 103.3% and is now trading at $8.40.
View which stocks have been most impacted by COVID-19.

Lianluo Smart shares reverse split on the morning of Monday, October 26th 2020. The 1-8 reverse split was announced on Friday, October 23rd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 23rd 2020. An investor that had 100 shares of Lianluo Smart stock prior to the reverse split would have 13 shares after the split.

Some companies that are related to Lianluo Smart include LENSAR (LNSR), InspireMD (NSPR), Neovasc (NVCN), Nephros (NEPHD), Sensus Healthcare (SRTS), AIT Therapeutics (AITB), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Delcath Systems (DCTH), Sintx Technologies (SINT), Daxor (DXR), InVivo Therapeutics (NVIV), Vivos (RDGL), Arch Therapeutics (ARTH) and Obalon Therapeutics (OBLN).
View all of LLIT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lianluo Smart investors own include Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), FuelCell Energy (FCEL), Biocept (BIOC), T2 Biosystems (TTOO), Actinium Pharmaceuticals (ATNM), Co-Diagnostics (CODX), Onconova Therapeutics (ONTX) and Sorrento Therapeutics (SRNE).

Lianluo Smart trades on the NASDAQ under the ticker symbol "LLIT."

Shares of LLIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLIT stock can currently be purchased for approximately $8.40.

Lianluo Smart has a market capitalization of $18.57 million and generates $380,000.00 in revenue each year.

Lianluo Smart employs 28 workers across the globe.

The official website for Lianluo Smart is www.lianluosmart.com.

Lianluo Smart is headquartered at Room 611 6th Floor BeiKong Technology Building No. 10 Baifuquan Road Changping District, Beijing F4, 102200.

Lianluo Smart's mailing address is Room 611 6th Floor BeiKong Technology Building No. 10 Baifuquan Road Changping District, Beijing F4, 102200. The medical equipment provider can be reached via phone at 86-10-8978-8107 or via email at [email protected]